Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma

Morten F Gjerstorff, Mette Pøhl, Karen E Olsen, Henrik J Ditzel

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with completely resected, early stage, primary NSCLC.
Original languageEnglish
JournalB M C Cancer
Volume13
Pages (from-to)466
Number of pages6
ISSN1471-2407
DOIs
Publication statusPublished - 2013

Fingerprint Dive into the research topics of 'Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma'. Together they form a unique fingerprint.

  • Cite this